Clene advances toward ALS drug filing but burns cash faster; material control weaknesses persist

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

Key Changes

• high

  FDA confirmed CNM-Au8 data may support accelerated NDA submission for ALS treatment in Q3 2026, advancing from 'potential path' guidance a year earlier, though Phase 3 confirmatory trial delayed 12-15 months to Q1 2027.

  MD&A: FDA Regulatory Pathway verify on EDGAR →
• high

  Net loss surged 977% to $8.1M in Q1 2026 vs $0.8M prior year, driven by $4.6M non-cash loss on January equity offering and unfavorable warrant liability revaluations, despite 78% cut in R&D spending to $0.3M.

  MD&A: Operating Results verify on EDGAR →
• high

  Material weaknesses in internal controls over financial reporting persist for third consecutive year (now covering 2024-2025 audits), with identical deficiencies in control environment, reconciliations, and IT systems despite ongoing remediation.

  Controls and Procedures verify on EDGAR →